Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOXXADO is a nasal spray formulation of naloxone hydrochloride, a pure opioid antagonist approved for rapid reversal of opioid overdose. It works by competitively blocking opioid receptors (μ, κ, σ) in the central nervous system to reverse respiratory depression, sedation, and hypotension. The product targets emergency and community settings where rapid, non-invasive opioid reversal is critical.
$0.312MPart D
Peak8.3 years to LOEKLOXXADO is in peak commercial phase with modest Part D penetration; teams are focused on market consolidation and access expansion rather than growth hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings suggest KLOXXADO lacks a dedicated brand team or is managed as part of Hikma's broader specialty/acute care portfolio. Career opportunities on this product are likely embedded in cross-functional teams rather than standalone brand positions.
Company
Worked on KLOXXADO at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.